Category
10 articles
Most clinicians read the abstract and nothing else — and abstracts are where statistical sleight of hand lives. This practical guide walks through five red flags you can detect in under two minutes, each paired with the one question that exposes it.
Older adults metabolize medications through physiological frameworks that diverge substantially from those of the middle-aged populations who dominate drug trials, yet standard dosing protocols rarely reflect this reality. Age-stratified pharmacokinetic data exists in the literature but has failed to migrate into clinical guidance, leaving physicians prescribing to a population whose bodies were never studied. The consequences—preventable toxicity, therapeutic failure, and excess hospitalization
The FDA's pediatric extrapolation pathway allows medications studied almost exclusively in adults to be prescribed to children on the assumption that disease progression and drug response are sufficiently similar. Decades of pharmacokinetic research suggest that assumption is frequently wrong. This article examines the regulatory architecture enabling that gap, the economic forces discouraging pediatric trials, and the clinical costs borne by patients who cannot advocate for better evidence.
Contemporary clinical decision-support tools continue to derive dosing recommendations from population-level averages, even as pharmacogenomic testing becomes increasingly accessible and affordable. The structural, economic, and regulatory inertia keeping individual metabolic profiles out of real-time prescribing workflows carries a measurable human cost. This investigation examines why precision medicine's most actionable frontier remains stranded outside the clinical mainstream.
Across the United States, competing electronic health record systems operate in near-total isolation from one another, creating dangerous blind spots in patient care. When clinicians cannot access a complete longitudinal health history, critical safety signals—drug interactions, prior adverse reactions, missed diagnoses—go undetected. This investigation examines the regulatory, technical, and financial forces sustaining these silos, and the patient harm accumulating in their shadow.
FDA approval is widely understood as a threshold of safety, yet the surveillance infrastructure designed to monitor drugs once they reach patients is riddled with structural deficiencies that allow adverse events to accumulate undetected for years. This investigation examines the regulatory gaps, financial disincentives, and institutional inertia that collectively undermine postmarket pharmacovigilance in the United States. The consequences, as several high-profile cases illustrate, extend far b
Landmark clinical discoveries validated in controlled trial settings routinely fail to translate into improved outcomes for patients in underserved communities, exposing a profound and underexamined gap between scientific progress and equitable care delivery. This analysis examines the infrastructure deficits, financial constraints, and systemic access barriers that concentrate the benefits of clinical innovation among already-advantaged populations, and surveys the policy and implementation str
Decades of clinical research conducted predominantly in white patient populations have produced an evidence base that frequently fails to account for the biological, pharmacological, and social heterogeneity of the United States' diverse patient population. This analysis documents the treatment harms that have emerged from this gap, examines the systemic barriers preventing equitable trial enrollment, and profiles the institutional reforms and policy interventions working to build a more inclusi
Machine learning and artificial intelligence are increasingly embedded in the architecture of clinical trials, from patient recruitment algorithms to real-time safety monitoring systems. Yet enthusiasm for these tools frequently outpaces the evidence supporting their reliability, and regulatory frameworks have struggled to keep pace with rapid deployment. This analysis weighs documented gains against underappreciated risks—and asks what rigorous validation of AI in clinical research would actual
Real-world evidence derived from electronic health records, claims databases, and patient registries is increasingly informing clinical decision-making and regulatory policy across US healthcare institutions. As the FDA and CMS accelerate frameworks for integrating observational data alongside traditional trial findings, precision medicine and population health strategies stand to be fundamentally transformed.